Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




SuperNova Diagnostics Enters Agreement with KSB Diagnostics of China

By LabMedica International staff writers
Posted on 23 Mar 2011
SuperNova Diagnostics, Inc. More...
(Germantown, MD, USA; and London, United Kingdom), a privately-held global diagnostics company for human and nonhuman health applications, signed an agreement with Shenzhen Kang Sheng Bao Bio-Technology Co., Ltd. (KSB; Shenzhen, China), a biotechnology diagnostics company specializing in research, manufacture, and distribution of in vitro diagnostic kits and research reagents in China and affiliated markets. Financial terms of the agreement were not disclosed.

AmpCrystal, SuperNova Diagnostics' lead technology with multiple product formats, allows minimally trained individuals (advanced CLIA-waived) to test for a wide range of protein analytes. It can detect directly unamplified DNA in human, animal, or environmental samples. AmpCrystal is hyper-dense, energy-mediated nanocrystals that can be utilized in a wide variety of diagnostic applications and configurations. The technology platform lends itself to both forward-integration into new product formats as well as backward compatible into existing open and closed diagnostic systems.

With three integrated capabilities (sample collector/processor, analytical disposable, and the readout device), AmpCrystal technology is simpler, more robust, faster, and significantly less expensive than existing POC systems.

A powerful nanochemistry, AmpCrystal, can deliver novel, next generation performance for pathogens, proteins, and directly measure DNA without polymerase chain reaction (PCR) with ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements. SuperNova can be utilized in a wide range of diagnostic formats (lateral flow, self-contained cartridges, microtiter, microarrays, closed systems, research products, and OEM).

"We are delighted to announce this agreement with KSB Diagnostics, a leader in China and Asia for diagnostics," said Neil Campbell, president & CEO of SuperNova Diagnostics. "This collaborative relationship allows SuperNova and KSB to expand R&D, manufacturing, and commercialization into one of the world's largest markets."

Through cooperation with its worldwide partners and introduction of advanced technology in the world, Shenzhen Kang Sheng Bao Bio-Technology Co. Ltd. provides the innovating diagnostic kits. Its goals are to make great efforts to serve the rapidly developing market in China and become one of the well-known corporations in the field of in vitro diagnostic reagents.

Related Links:
SuperNova Diagnostics, Inc.
Kang Sheng Bao Bio-Technology Co., Ltd.


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.